Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist Stimulates Insulin Secretion in Rodents and From Human Islets
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The clinical effectiveness of parenterally-administered glucagon-like peptide-1 (GLP-1) mimetics to improve glucose control in patients suffering from type 2 diabetes strongly supports discovery pursuits aimed at identifying and developing orally active, small molecule GLP-1 receptor agonists. The purpose of these studies was to identify and characterize novel nonpeptide agonists of the GLP-1 receptor. RESEARCH DESIGN AND METHODS: Screening using cells expressing the GLP-1 receptor and insulin secretion assays with rodent and human islets were used to identify novel molecules. The intravenous glucose tolerance test (IVGTT) and hyperglycemic clamp characterized the insulinotropic effects of compounds in vivo. RESULTS: Novel low molecular weight pyrimidine-based compounds that activate the GLP-1 receptor and stimulate glucose-dependent insulin secretion are described. These molecules induce GLP-1 receptor-mediated cAMP signaling in HEK293 cells expressing the GLP-1 receptor and increase insulin secretion from rodent islets in a dose-dependent manner. The compounds activate GLP-1 receptor signaling, both alone or in an additive fashion when combined with the endogenous GLP-1 peptide; however, these agonists do not compete with radiolabeled GLP-1 in receptor-binding assays. In vivo studies using the IVGTT and the hyperglycemic clamp in Sprague Dawley rats demonstrate increased insulin secretion in compound-treated animals. Further, perifusion assays with human islets isolated from a donor with type 2 diabetes show near-normalization of insulin secretion upon compound treatment. CONCLUSIONS: These studies characterize the insulinotropic effects of an early-stage, small molecule GLP-1 receptor agonist and provide compelling evidence to support pharmaceutical optimization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“One study showed that compound B almost normalised insulin secretion in human islets isolated from a T2D donor.286”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [286]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fredriksson, R., Lagerström, M. C., Lundin, L.-G., & Schiöth, H. B. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.6.1256 · Cited by 2,941
Structural diversity of G protein-coupled receptors and significance for drug discovery
Lagerström, M. C., & Schiöth, H. B. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2518 · Cited by 1,492
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129 · cited 1×
“In addition, these therapies often reduce body weight and improve several cardiovascular parameters (5,6).”
BackgroundVilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884 · cited 1×
“Impairment of the incretin effect, including reduced secretion of glucagonlike peptide-1 (GLP-1) (1,2), is implicated in the progression of pancreatic islet dysfunction in type 2 diabetic patients.”
BackgroundMojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 882 · cited 2×
“GLP-1 is a glucose-dependent insulinotropic peptide (27,28).”
BackgroundDeterminants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869 · cited 1×
“Impairment of the incretin effect, including reduced secretion of glucagonlike peptide-1 (GLP-1) (1,2), is implicated in the progression of pancreatic islet dysfunction in type 2 diabetic patients.”
BackgroundGöke, R., Fehmann, H. C., Linn, T., Schmidt, H., Krause, M., Eng, J., & Göke, B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36565-2 · Cited by 837 · cited 2×
“B: The competitive GLP-1 receptor peptide antagonist exendin (9-39) blunted GLP-1 peptide activity but did not reduce compound B-induced signaling.”
BackgroundMethodKlonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699 · cited 1×
“In addition, these therapies often reduce body weight and improve several cardiovascular parameters (5,6).”
BackgroundAllosteric Modulation of G Protein–Coupled Receptors
May, L. T., Leach, K., Sexton, P. M., & Christopoulos, A. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105159 · Cited by 695
Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut
Holst, J. J., Ørskov, C., Vagn Nielsen, O., & Schwartz, T. W. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)81430-8 · Cited by 615 · cited 2×
“GLP-1 is a glucose-dependent insulinotropic peptide (27,28).”
BackgroundThorens, B., Porret, A., Bühler, L., Deng, S.-P., Morel, P., & Widmann, C. (1993) · Diabetes · doi:10.2337/diab.42.11.1678 · Cited by 558 · cited 3×
“B: The competitive GLP-1 receptor peptide antagonist exendin (9-39) blunted GLP-1 peptide activity but did not reduce compound B-induced signaling.”
BackgroundMethodMechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors
Hoare, S. R. J. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03370-2 · Cited by 379 · cited 3×
“Accordingly, class B GPCRs represent some of the most attractive targets for therapeutic intervention, and this is borne out by regulatory approval of several large molecule biotherapeutics, including PTH (teriparatide, Forteo) for osteoporosis, exendin-4 (exenatide, Byetta) and liraglutide (Victoza) for type 2 diabet…”
BackgroundUnderwood, C. R., Garibay, P., Knudsen, L. B., Hastrup, S., Peters, G. H., Rudolph, R., & Reedtz-Runge, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.033829 · Cited by 295 · cited 2×
“Recent studies have defined the structure of the GLP-1 peptide-bound ECD of the GLP-1 receptor (36,37).”
BackgroundCrystal Structure of the Ligand-bound Glucagon-like Peptide-1 Receptor Extracellular Domain
Runge, S., Thøgersen, H., Madsen, K., Lau, J., & Rudolph, R. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708740200 · Cited by 291 · cited 2×
“Recent studies have defined the structure of the GLP-1 peptide-bound ECD of the GLP-1 receptor (36,37).”
BackgroundSmall-molecule agonists for the glucagon-like peptide 1 receptor
Knudsen, L. B., Kiel, D., Teng, M., Behrens, C., Bhumralkar, D., Kodra, J. T., Holst, J. J., Jeppesen, C. B., Johnson, M. D., de Jong, J. C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605701104 · Cited by 232 · cited 5×
“Finally, although not to the extent reported for the quinoxalines (13), it should be noted that high concentrations of compound A or compound B display lower signaling in the in vitro assays.”
BackgroundInfluentialIncretin-Based Therapies in Type 2 Diabetes Mellitus
Chia, C. W., & Egan, J. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2109 · Cited by 223
Laburthe, M., Couvineau, A., & Tan, V. (2007) · Peptides · doi:10.1016/j.peptides.2007.04.026 · Cited by 189 · cited 1×
“B: The competitive GLP-1 receptor peptide antagonist exendin (9-39) blunted GLP-1 peptide activity but did not reduce compound B-induced signaling.”
BackgroundTurn-on switch in parathyroid hormone receptor by a two-step parathyroid hormone binding mechanism
Castro, M., Nikolaev, V. O., Palm, D., Lohse, M. J., & Vilardaga, J.-P. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503942102 · Cited by 176 · cited 1×
“B: The competitive GLP-1 receptor peptide antagonist exendin (9-39) blunted GLP-1 peptide activity but did not reduce compound B-induced signaling.”
BackgroundA nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db / db mice
Chen, D., Liao, J., Li, N., Zhou, C., Liu, Q., Wang, G., Zhang, R., Zhang, S., Lin, L., Chen, K., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610173104 · Cited by 169 · cited 4×
“Much activity has been expended searching for GLP-1 receptor small molecule agonists, and up to this point, only two bona fide agonists have been described: low molecular weight substituted quinoxalines (13–16) and the large cyclobutane derivative, Boc-5 (17).”
BackgroundInfluentialRickard, D. J., Wang, F., Rodriguez-Rojas, A.-M., Wu, Z., Trice, W. J., Hoffman, S. J., Votta, B. J., Stroup, G. B., Kumar, S., & NUTTALL, M. E. (2006) · Bone · doi:10.1016/j.bone.2006.06.010 · Cited by 168 · cited 2×
“In contrast, minimal success has been achieved in the discovery of class B small molecule agonists; isolated examples include the discovery of small molecule agonists of the PTH receptor (31), the calcitonin receptor (32,33), and the CRF receptor (34).”
BackgroundLaburthe, M., Couvineau, A., Gaudin, P., Maoret, J.-J., Rouyer‐Fessard, C., & Nicole, P. (2006) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb17476.x · Cited by 148
Monami, M., Marchionni, N., & Mannucci, E. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0101 · Cited by 146 · cited 1×
“For example, treatment with either exenatide or liraglutide reduces fasting hyperglycemia and results in sustained lowering of glycosylated A1C (A1C) levels (3,4).”
BackgroundLópez de Maturana, R., Willshaw, A., Kuntzsch, A., Rudolph, R., & Donnelly, D. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212147200 · Cited by 103 · cited 2×
“B: The competitive GLP-1 receptor peptide antagonist exendin (9-39) blunted GLP-1 peptide activity but did not reduce compound B-induced signaling.”
BackgroundAllosteric Modulators of GABAB Receptors: Mechanism of Action and Therapeutic Perspective
Pin, J., & Prézeau, L. (2007) · Current Neuropharmacology · doi:10.2174/157015907781695919 · Cited by 90 · cited 2×
“B: The competitive GLP-1 receptor peptide antagonist exendin (9-39) blunted GLP-1 peptide activity but did not reduce compound B-induced signaling.”
BackgroundSmall molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor
Teng, M., Johnson, M. D., Thomas, C., Kiel, D., Lakis, J., Kercher, T., Aytes, S. A., Kostrowicki, J., Bhumralkar, D. R., Truesdale, L. K., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.06.086 · Cited by 67 · cited 1×
“B: The competitive GLP-1 receptor peptide antagonist exendin (9-39) blunted GLP-1 peptide activity but did not reduce compound B-induced signaling.”
BackgroundFu, L., & Wang, R. (2008) · Journal of Molecular Modeling · doi:10.1007/s00894-008-0372-2 · Cited by 46 · cited 3×
“around the structural determinants of peptide and small molecule binding to the juxtamembrane regions of the GLP-1 receptor (38).”
BackgroundBahekar, R. H., Jain, M. R., Gupta, A. A., Goel, A., Jadav, P. A., Patel, D. N., Prajapati, V. M., & Patel, P. R. (2007) · Archiv der Pharmazie · doi:10.1002/ardp.200700024 · Cited by 39 · cited 1×
“B: The competitive GLP-1 receptor peptide antagonist exendin (9-39) blunted GLP-1 peptide activity but did not reduce compound B-induced signaling.”
BackgroundIrwin, N., Flatt, P. R., Patterson, S., & Green, B. D. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.11.022 · Cited by 38 · cited 3×
“GLP-1 receptor-expressing cellular systems, and the quinoxalines clearly induce glucose-stimulated insulin secretion in vitro from rodent islets and ex vivo via perfused pancreas (13,16).”
BackgroundHargrove, D. M., Nardone, N. A., Persson, L. M., Parker, J. C., & Stevenson, R. W. (1995) · Metabolism · doi:10.1016/0026-0495(95)90021-7 · Cited by 36 · cited 2×
“The insulin secretory response induced by compound B observed using both the IVGTT and hyperglycemic clamp methods is consistent with pharmacology demonstrated by peptide GLP-1 receptor agonists (29) and supports the results obtained from the islet assays showing that compound B is a glucose-dependent insulin secretag…”
BackgroundResultHoare, S. R. J., Fleck, B. A., Gross, R. S., Crowe, P. D., Williams, J. P., & Grigoriadis, D. E. (2008) · Molecular Pharmacology · doi:10.1124/mol.107.042978 · Cited by 29 · cited 2×
“In contrast, minimal success has been achieved in the discovery of class B small molecule agonists; isolated examples include the discovery of small molecule agonists of the PTH receptor (31), the calcitonin receptor (32,33), and the CRF receptor (34).”
BackgroundKatayama, T., Furuya, M., Yamaichi, K., Konishi, K., Sugiura, N., Murafuji, H., Magota, K., Saito, M., Tanaka, S., & Oikawa, S. (2001) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(01)00125-8 · Cited by 23 · cited 2×
“In contrast, minimal success has been achieved in the discovery of class B small molecule agonists; isolated examples include the discovery of small molecule agonists of the PTH receptor (31), the calcitonin receptor (32,33), and the CRF receptor (34).”
BackgroundBRENNER, M., Gromada, J., Efanov, A. M., Bokvist, K. B., & MEST, H. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1304.042 · Cited by 22 · cited 2×
“B: The competitive GLP-1 receptor peptide antagonist exendin (9-39) blunted GLP-1 peptide activity but did not reduce compound B-induced signaling.”
BackgroundMethodSelf-citationGlucose-induced insulin secretion is potentiated by a new imidazoline compound
Mest, H.-J. X. F. R., Raap, A., Schloos, J., Treinies, I., Paal, M., Giese, U., & Koivisto, V. A. (2001) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s002100100415 · Cited by 21 · cited 2×
“B: The competitive GLP-1 receptor peptide antagonist exendin (9-39) blunted GLP-1 peptide activity but did not reduce compound B-induced signaling.”
BackgroundMethodBoros, E. E., Cowan, D. J., Cox, R. F., Mebrahtu, M., Rabinowitz, M. H., Thompson, J. B., & Wolfe, L. A. (2005) · The Journal of Organic Chemistry · doi:10.1021/jo050370b · Cited by 18 · cited 3×
“With the exception of low-nanomolar pyrazolopyridine calcitonin receptor partial agonists (33), class B GPCR agonist molecules have micromolar potencies.”
BackgroundBrenner, M. B., & Mest, H.-J. (2004) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2004.01.002 · Cited by 11 · cited 2×
“B: The competitive GLP-1 receptor peptide antagonist exendin (9-39) blunted GLP-1 peptide activity but did not reduce compound B-induced signaling.”
BackgroundMethodSelf-citation
Cited by
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
Emerging paradigms in GPCR allostery: implications for drug discovery
Wootten, D., Christopoulos, A., & Sexton, P. M. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4052 · Cited by 498
Reed, J., Bain, S., & Kanamarlapudi, V. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s319895 · Cited by 441
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
Athauda, D., & Foltynie, T. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.013 · Cited by 383
Metadata
- Authors
- Sloop, K. W., Willard, F. S., Brenner, M. B., Ficorilli, J., Valasek, K., Showalter, A. D., Farb, T. B., Cao, J. X. C., Cox, A. L., Michael, M. D., Gutierrez Sanfeliciano, S. M., Tebbe, M. J., & Coghlan, M. J.
- Affiliations
- Eli Lilly (United States) (US)
- Discovery Chemistry Research and Technologies, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
- Corresponding author
- Sloop, Kyle W.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2010-09-07
- Volume
- 59
- Issue
- 12
- Pages
- 3099-3107
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2992771
- OpenAlex
- W2142458050
- Cited by
- 143
- References
- 35
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 5 · 2023: 4 · 2022: 4 · 2021: 14 · 2020: 12 · 2019: 8 · 2018: 3 · 2017: 7 · 2016: 10 · 2015: 10 · 2014: 17 · 2013: 19 · 2012: 12
- FWCI
- 10.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- GLP-1 receptor agonists, small molecule agonists, insulin secretion, type 2 diabetes, pyrimidine derivatives, cAMP signaling, glucose-dependent insulin secretion, human pancreatic islets, oral GLP-1 receptor agonists, drug discovery
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Insulin Secretion, Cyclic AMP, Animals, Gastric Inhibitory Polypeptide, Glucagon, Glucose Tolerance Test, Humans, Insulin, Islets of Langerhans, Luciferases, Male, Parathyroid Hormone, Vasoactive Intestinal Peptide, Rats, Sprague-Dawley, Genes, Reporter, Receptors, Glucagon, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.